Clinical Trials Management Today's Research... Tomorrow's Cures

Relationships & Accomplishments

SCYNEXIS Announces FDA Approval of BREXAFEMME®

June 7, 2021 | Posted in: Relationships & Accomplishments
SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections June 02, 2021 07:30 ET | Source: ... » Read More


Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream

June 7, 2021 | Posted in: Relationships & Accomplishments
June 3, 2021 Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis – NDA is supported by positive data from the Pha... » Read More


Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®

May 27, 2021 | Posted in: Relationships & Accomplishments
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids May 26, 2021 at 4:15 PM EDT ... » Read More


Incyte Announces Positive Results from Phase 3 TRuE-V Program

May 19, 2021 | Posted in: Relationships & Accomplishments
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo May 17, 2021  DownloadPDF Format (opens in new window) ... » Read More


Phathom Pharmaceuticals Announces HP-301 Topline Results

May 5, 2021 | Posted in: Relationships & Accomplishments
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints A... » Read More


Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis

May 11, 2020 | Posted in: Relationships & Accomplishments
Otezla Treatment Resulted in Significant Improvements in Measures of Mild-to-Moderate Psoriasis Compared With Placebo Data Will be Submitted to the U.S. Food and Drug Administration (FDA) for I... » Read More


Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control

December 26, 2018 | Posted in: Relationships & Accomplishments
– Top-Line Phase 3 Data Demonstrate 86.0% Efficacy, which Met Primary Study Endpoint, and 98.7% Efficacy when Used as Directed – – Q2 2019 New Drug Application (NDA) Resubmiss... » Read More


RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA for H.pylori Infection

December 6, 2018 | Posted in: Relationships & Accomplishments
RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection   • The ERADICATE Hp2 confirmatory Phase 3 study su... » Read More


Sienna Biopharmaceuticals Announces Its Topical, Non-Steroid TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials

December 6, 2018 | Posted in: Relationships & Accomplishments
Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoria... » Read More


Novartis Phase III Study Reduces Cardiovascular Risk

June 27, 2017 | Posted in: Relationships & Accomplishments
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack Basel, June 22, 2017 –Novartis today announced topline results from ... » Read More


« Previous 1 2 Next »